← Eichor
Condition: Her 2 Positive Breast Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Her 2 Positive Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac
Phase 3 · 590 location(s) · SWOG Cancer Research Network · NCT03418961Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
Phase N/A · 1 location(s) · Seoul National University Hospital · NCT06928818Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2-
Phase 3 · 1 location(s) · Genentech, Inc. · NCT07541079Pre Operative Trastuzumab in Operable Breast Cancer
Phase 3 · 1 location(s) · Dr Rajendra A. Badwe · NCT01785420Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
Phase 1/Phase 2 · 11 location(s) · Vironexis Biotherapeutics Inc. · NCT07192432NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline
Phase 2 · 8 location(s) · Swiss Cancer Institute · NCT06452394TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
Phase 3 · 1 location(s) · Fudan University · NCT05901428Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2
Phase N/A · 1 location(s) · University Hospital, Basel, Switzerland · NCT07546695RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastati
Phase 2/Phase 3 · 109 location(s) · Hoffmann-La Roche · NCT07413939Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT05325632Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subje
Phase 3 · 179 location(s) · Greenwich LifeSciences, Inc. · NCT05232916A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Ad
Phase 1 · 15 location(s) · TerSera Therapeutics LLC · NCT07310420Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Gire
Phase 1 · 4 location(s) · Genentech, Inc. · NCT07214662A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
Phase 1/Phase 2 · 2 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT06202261Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer
Phase 2 · 1 location(s) · Shanghai Jiao Tong University School of Medicine · NCT05891561FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Phase 1 · 8 location(s) · Regor Pharmaceuticals Inc. · NCT05304962A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
Phase 1 · 6 location(s) · Edgewood Oncology Inc. · NCT04872166Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for
NA · 1 location(s) · Medical College of Wisconsin · NCT06106477Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant
Phase N/A · 2 location(s) · Société Algérienne de Formation et Recherche en Oncologie · NCT07542496RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
Phase 1 · 4 location(s) · Mridula George, MD · NCT06139107A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05035836Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic B
Phase 2 · 8 location(s) · SCRI Development Innovations, LLC · NCT05748834Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.
Phase 2 · 1 location(s) · University of California, San Diego · NCT07227233A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth
Phase 2 · 78 location(s) · Eli Lilly and Company · NCT07287098A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Meta
Phase 2 · 53 location(s) · Puma Biotechnology, Inc. · NCT06369285Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Phase 3 · 284 location(s) · AstraZeneca · NCT04862663PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Phase 2 · 1 location(s) · Kristina A. Fanucci · NCT07222215NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.
Phase N/A · 1 location(s) · Henan Cancer Hospital · NCT06781281
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.